Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist

Frances McManus, Gordon T McInnes, John M C Connell

    Research output: Contribution to journalArticlepeer-review

    32 Citations (Scopus)


    Increasing recognition of the role of aldosterone in cardiovascular disease has been supported by a significant body of evidence from animal models. This evidence has been translated into clinical practice, and large-scale, randomized, placebo-controlled trials have confirmed the beneficial effects of mineralocorticoid blockade in patients with heart failure. As a consequence, there has been a resurgence in the use of mineralocorticoid-receptor antagonists in clinical practice that has prompted the search for a potent and specific antagonist without the sexual side effects of spironolactone. Eplerenone, a mineralocorticoid-receptor antagonist with minimal binding to the progesterone and androgen receptors, is now licensed for treatment of heart failure in Europe and heart failure and hypertension in the US; it has also been proposed as a treatment for a variety of cardiovascular conditions. This article reviews the current concepts of the actions of aldosterone at a cellular level. Recent findings regarding its role as a cardiovascular hormone, both in animal models and human studies, are discussed. We also describe the development of mineralocorticoid-receptor blockers following the isolation of aldosterone and discuss the subsequent search for a specific mineralocorticoid antagonist. In addition we detail the effects of eplerenone in a number of clinical situations and outline its potential future applications.
    Original languageEnglish
    Pages (from-to)44-52
    Number of pages9
    JournalNature Reviews Endocrinology
    Issue number1
    Publication statusPublished - 2008


    Dive into the research topics of 'Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist'. Together they form a unique fingerprint.

    Cite this